Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.020 CAD
−2.96 M CAD
254.90 K CAD
112.80 M
About AEQUUS PHARMACEUTICALS INC
Sector
CEO
Douglas Glen Janzen
Headquarters
Vancouver
Website
Founded
2013
FIGI
BBG0089LFZ20
Aequus Pharmaceuticals, Inc. engages in the development and commercialization of alternatives to currently approved drugs. Its products include, Tacrolimus IR, are used for the treatment of refractory rejection in patients receiving allogenic liver, kidney or heart transplants; and Vistitan, and are used for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. The company was founded by Fotios Plakogiannis, Charlie Perperidis, Peter Gregory Wilson, and Alexander Goumeniouk on January 3, 2013 and is headquartered in Vancouver, Canada.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of AQS is 0.005 CAD — it hasn't changed in the past 24 hours. Watch AEQUUS PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSXV exchange AEQUUS PHARMACEUTICALS INC stocks are traded under the ticker AQS.
AQS stock has fallen by −50.00% compared to the previous week, the month change is a −50.00% fall, over the last year AEQUUS PHARMACEUTICALS INC has showed a −85.71% decrease.
AQS stock is 0.00% volatile and has beta coefficient of 0.85. Track AEQUUS PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is AEQUUS PHARMACEUTICALS INC there?
Today AEQUUS PHARMACEUTICALS INC has the market capitalization of 663.17 K, it has decreased by −50.00% over the last week.
Yes, you can track AEQUUS PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
AQS net income for the last quarter is −614.73 K CAD, while the quarter before that showed −683.03 K CAD of net income which accounts for 10.00% change. Track more AEQUUS PHARMACEUTICALS INC financial stats to get the full picture.
No, AQS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AEQUUS PHARMACEUTICALS INC EBITDA is −2.31 M CAD, and current EBITDA margin is −1.05 K%. See more stats in AEQUUS PHARMACEUTICALS INC financial statements.
Like other stocks, AQS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AEQUUS PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AEQUUS PHARMACEUTICALS INC technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AEQUUS PHARMACEUTICALS INC stock shows the strong sell signal. See more of AEQUUS PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.